Reaction

Encephalitis Viral reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,195 reports · 52 co-occurring drugs

As of the last recalculation, Encephalitis Viral appears in 1,195 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 173.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Thiotepa88173.2174.8
Micafungin Sodium55118.4119.2
Fludarabine Phosphate16987.087.4
Trimethoprim5178.779.0
Anti-Thymocyte Globulin (Rabbit)2657.457.5
Busulfan4248.148.3
Alemtuzumab4138.238.3
Valganciclovir Hydrochloride Powder,2637.938.0
Mycophenilic Acid3933.933.9
Ganciclovir Sodium2033.533.5
Mycophenolate Mofetil Hydrochloride21533.333.4
Mycophenolate Mofetil21333.033.1
Ganciclovir1729.329.4
Melphalan3729.229.3
Valganciclovir3028.428.4
Valganciclovir Hydrochloride3028.428.4
Melphalan Hydrochloride3928.028.0
Tacrolimus Ointment 0.1%16326.226.3
Tacrolimus Extended-Release Capsules16326.226.2
Tacrolimus19425.625.6
Basiliximab1624.024.0
Mycophenolic Acid4223.723.7
Everolimus Tablets2223.323.3
Cyclosporine11620.020.0
Anakinra1617.017.0
Bleomycin Sulfate1017.017.0
Ritonavir 100 Mg1416.516.5
Atazanavir1315.915.9
Bendamustine Hcl1415.915.9
Sirolimus1215.715.7
Posaconazole Delayed-Release914.414.4
Acyclovir8714.214.2
Tenofovir Disoproxil Fumarate Tablets714.214.2
Rituximab15114.114.1
Cyclophosphamide Injection, Solution12513.613.6
Cyclophosphamide12513.613.6
Cyclophosphamide For Injection12513.613.6
Meropenem2413.313.3
Abacavir Sulfate712.612.6
Etoposide4711.511.6
Ritonavir1911.511.5
Posaconazole1010.810.8
Lamivudine Oral149.79.7
Lamivudine179.79.7
Obinutuzumab88.58.5
Thalidomide167.77.7
Ifosfamide97.37.3
Azacitidine For76.76.7
Tenofovir Disoproxil Fumarate115.85.8
Temozolomide75.85.8
Certolizumab Pegol365.55.5
Diroximel Fumarate34.44.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.